BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 15501951)

  • 1. Evaluating the efficiency of targeted designs for randomized clinical trials.
    Simon R; Maitournam A
    Clin Cancer Res; 2004 Oct; 10(20):6759-63. PubMed ID: 15501951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On the efficiency of targeted clinical trials.
    Maitournam A; Simon R
    Stat Med; 2005 Feb; 24(3):329-39. PubMed ID: 15551403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients.
    Freidlin B; Simon R
    Clin Cancer Res; 2005 Nov; 11(21):7872-8. PubMed ID: 16278411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker-adaptive threshold design: a procedure for evaluating treatment with possible biomarker-defined subset effect.
    Jiang W; Freidlin B; Simon R
    J Natl Cancer Inst; 2007 Jul; 99(13):1036-43. PubMed ID: 17596577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized phase II designs in cancer clinical trials: current status and future directions.
    Lee JJ; Feng L
    J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of randomized discontinuation design.
    Freidlin B; Simon R
    J Clin Oncol; 2005 Aug; 23(22):5094-8. PubMed ID: 15983399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design.
    Taylor JM; Braun TM; Li Z
    Clin Trials; 2006; 3(4):335-48. PubMed ID: 17060208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
    El-Maraghi RH; Eisenhauer EA
    J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-arm clinical trials of new agents: some design considerations.
    Freidlin B; Korn EL; Gray R; Martin A
    Clin Cancer Res; 2008 Jul; 14(14):4368-71. PubMed ID: 18628449
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An examination of the efficiency of the sequential parallel design in psychiatric clinical trials.
    Tamura RN; Huang X
    Clin Trials; 2007; 4(4):309-17. PubMed ID: 17848492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers.
    Glynn RJ; Brookhart MA; Stedman M; Avorn J; Solomon DH
    Med Care; 2007 Oct; 45(10 Supl 2):S38-43. PubMed ID: 17909381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selection designs for pilot studies based on survival.
    Liu PY; Dahlberg S; Crowley J
    Biometrics; 1993 Jun; 49(2):391-8. PubMed ID: 8369375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving the design of phase II trials of cytostatic anticancer agents.
    Stone A; Wheeler C; Barge A
    Contemp Clin Trials; 2007 Feb; 28(2):138-45. PubMed ID: 16843736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cross-validated adaptive signature design.
    Freidlin B; Jiang W; Simon R
    Clin Cancer Res; 2010 Jan; 16(2):691-8. PubMed ID: 20068112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A simple sample size formula for analysis of covariance in randomized clinical trials.
    Borm GF; Fransen J; Lemmens WA
    J Clin Epidemiol; 2007 Dec; 60(12):1234-8. PubMed ID: 17998077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II clinical trial design: methods in translational research from the Genitourinary Committee at the Eastern Cooperative Oncology Group.
    Gray R; Manola J; Saxman S; Wright J; Dutcher J; Atkins M; Carducci M; See W; Sweeney C; Liu G; Stein M; Dreicer R; Wilding G; DiPaola RS
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):1966-9. PubMed ID: 16609005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reliability, effect size, and responsiveness of health status measures in the design of randomized and cluster-randomized trials.
    Diehr P; Chen L; Patrick D; Feng Z; Yasui Y
    Contemp Clin Trials; 2005 Feb; 26(1):45-58. PubMed ID: 15837452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relative efficiency of unequal versus equal cluster sizes in cluster randomized and multicentre trials.
    van Breukelen GJ; Candel MJ; Berger MP
    Stat Med; 2007 Jun; 26(13):2589-603. PubMed ID: 17094074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial design issues in the era of targeted therapies.
    Schiller JH
    Clin Cancer Res; 2004 Jun; 10(12 Pt 2):4281s-4282s. PubMed ID: 15217975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.